Developed on JHM Biopharma’s synthetic biology platform, JunoRegen™ ultra long-acting growth hormone is produced in E. coli with human IgG4 Fc as a long-acting carrier. Using inclusion body process ing (denaturation/renaturation), assembly, and multi-step purification, the product achieves a significantly extended half-life.

Key Features

• Natural Fc carrier with low immunogenicity
• Novel molecular structure, designed for an extended half-life
• Biweekly dosing, improving patient adherence
• Prokaryotic expression system, significantly reducing production cost